Contains predictive markers, including mutations, Gene amplifications and detection of MSI.
The Predictive Analysis for THerapy (PATH) panel covers clinically relevant predictive markers for molecular testing of lung cancer, colorectal cancer, melanoma, and GIST. Design in close collaboration with the laboratory of Tumor Genetics at Radboud university medical center and the Dutch PATH project.
The detection of a wide range of aberrations, such as BRAF codon 600 mutations, MET mutation and amplification, ERBB2 (HER2) mutation and amplification and MSI, make it also useful for a broader set of tumours. The PATH panel is the result of a cooperation between clinical geneticists and molecular biologists of 4 academic centres, pharma companies and several scientific societies. For more relevant information and clinical testing results, we refer to: Steeghs et al., BMC Cancer 2020
The revolutionary smMIP based enrichment method, in combination with the straightforward kit design provides a number of unique features.
✔ Includes Microsatellite Instability (MSI) Detection (>50 independent markers)
✔ Uses Unique Molecular Identifiers (UMI) to perform true quantitative mutation and CNV detection
✔ Low input DNA (10-100 ng), Fresh Frozen or FFPE derived